The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharma: anti-HIV compositions. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
See Also:
Anti-HIV compositions is a key innovation area in genomics
Antiretroviral therapy is used for the treatment of HIV. Anti-HIV therapies include of non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors, fusion inhibitors, C-C chemokine receptor type 5 (CCR5) antagonists, integrase strand transfer inhibitors (INSTI), and post attachment inhibitor drugs. These drugs help to decrease the viral load and prevent the transmission of the infection.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 290+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-HIV compositions.
Key players in anti-HIV compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to anti-HIV compositions
Source: GlobalData Patent Analytics
GSK is the leading patent filer in anti-HIV composition drugs. Its subsidiary VIV Healthcare is a pioneer in developing HIV drugs. VIV Healthcare has several assets such as Triumeq and Tivicay, which are well established in the market. It also has several pipeline assets in various stages of development targeting various parts of the virus.
In terms of application diversity, Theraclone Sciences is the top company, followed by Grifols and Bristol-Myers Squibb. By means of geographic reach, Curevac holds the top position. Academia Sinica and Vaxart are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
